27 assets in Juvenile Myelomonocytic Leukemia

Therapeutic assets addressing Juvenile Myelomonocytic Leukemia, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cyclophosphamide Juvenile Myelomonocytic Leukemia	Masonic Cancer Center, University of Minnesota	P4	BBB (75)
Busulfanum Juvenile Myelomonocytic Leukemia	Masonic Cancer Center, University of Minnesota	P4	BBB (72)
Thiotepa Juvenile Myelomonocytic Leukemia	St. Jude Children's Research Hospital	P3	BBB (72)
Fludarabine Juvenile Myelomonocytic Leukemia	Children's Oncology Group	P3	BB (71)
Nivestim Juvenile Myelomonocytic Leukemia	Masonic Cancer Center, University of Minnesota	P3	BB (70)
Tacrolimus Juvenile Myelomonocytic Leukemia	Masonic Cancer Center, University of Minnesota	P2	BB (69)
Rituximab Juvenile Myelomonocytic Leukemia	Masonic Cancer Center, University of Minnesota	P3	BB (66)
Alemtuzumab Juvenile Myelomonocytic Leukemia	Diane George	P2	BB (65)
Anti-Human T-Lymphocyte Immunoglobulin, Rabbit Juvenile Myelomonocytic Leukemia	Masonic Cancer Center, University of Minnesota	P2	B (63)
Melphalan Juvenile Myelomonocytic Leukemia	Masonic Cancer Center, University of Minnesota	P2	B (63)
Methotrexate Juvenile Myelomonocytic Leukemia	Children's Oncology Group	P2	B (63)
Azacitidine Juvenile Myelomonocytic Leukemia	Johns Hopkins All Children's Hospital	P2	B (62)
Abatacept Recombinant Juvenile Myelomonocytic Leukemia	Federal Research Institute of Pediatric Hematology, Oncology and Immunology	P3	B (60)
Cytarabine Juvenile Myelomonocytic Leukemia	Children's Oncology Group	P2	B (60)
Vedolizumab Juvenile Myelomonocytic Leukemia	Federal Research Institute of Pediatric Hematology, Oncology and Immunology	P3	CCC (55)
Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells Juvenile Myelomonocytic Leukemia	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Blinatumomab Juvenile Myelomonocytic Leukemia	St. Jude Children's Research Hospital	P2	CCC (53)
cd45ra-depleted dli Juvenile Myelomonocytic Leukemia	St. Jude Children's Research Hospital	P2	CCC (53)
Hpc, Cord Blood Juvenile Myelomonocytic Leukemia	St. Jude Children's Research Hospital	P2	CCC (53)
Mesna Juvenile Myelomonocytic Leukemia	St. Jude Children's Research Hospital	P2	CCC (53)
Sirolimus Juvenile Myelomonocytic Leukemia	St. Jude Children's Research Hospital	P2	CCC (53)
Vorinostat Juvenile Myelomonocytic Leukemia	Johns Hopkins All Children's Hospital	P1	CC (46)
cd8+ and cd4+ donor memory t-cells-expressing ha1-specific tcr Juvenile Myelomonocytic Leukemia	Fred Hutchinson Cancer Center	P1	CC (43)
Ciml-Nk Cells Juvenile Myelomonocytic Leukemia	Dana-Farber Cancer Institute	P1	CC (43)
Dna, D(3'-Amino-3'-Deoxy-P-Thio)(T-A-G-G-G-T-T-A-G-A-C-A-A), 5'-(O-(2-Hydroxy-3-((1-Oxohexadecyl)Amino)Propyl) Hydrogen Phosphorothioate) Juvenile Myelomonocytic Leukemia	Children's Oncology Group	P1	CC (43)
Hpc-A Juvenile Myelomonocytic Leukemia	St. Jude Children's Research Hospital	P2	CC (43)
Hydrocortisone Juvenile Myelomonocytic Leukemia	Children's Oncology Group	P1	CC (43)